1. Individualizing Treatment Options in Advanced ER-Positive Breast Cancer

3. Introduction Advanced ER-Positive BC

4. Maximizing Time of Tumor Endocrine Sensitivity

5. Case Study 1

6. Interactivity Question 1

7. 1st Line Endocrine Therapy in ABC: Choice of ET + /- CDK 4/6 inhibitor

8. FALCON: Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced BC

9. FALCON Trial Results

10. FALCON PFS by Patient Subgroups

12. Case Study 2

13. Interactive Question 2

14. MONALEESA-2: Ribociclib Plus Letrozole vs Letrozole in Hormone Receptor-Positive Advanced BC

15. MONALEESA-2 Results

16. MONALEESA-2 Safety Profile

17. MONALEESA-2 Subgroup Analysis

18. PALOMA-2 Palbociclib Plus Letrozole vs Letrozole Alone

19. PALOMA-2 Results

20. PALOMA-2 AE Summary

21. Case Study 3

22. Case Study 1 continued

23. Interactive Question 3

24. PALOMA-3 Palbociclib Plus Fulvestrant in Premenopausal/Perimenopausal mBC

25. PALOMA-3 Results

26. PALOMA-3 Safety Results

27. PALOMA-3 and SoFEA ESR1 Mutations

28. ESR1 Mutations PALOMA-3 Results

29. BOLERO-2: Everolimus Plus Exemestane vs Placebo Plus Exemestane

30. BOLERO-2 Results

31. BOLERO-2 Most Common Grade 3/4 AEs

32. Conclusions/Key Takeaways